Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly with chemotherapy is approved by the FDA for endometrial cancer
August 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline), followed by dostarlimab-gxly as a single agent, was approved by the Food and Drug Administration for the treatment of primary advanced or recurrent endometrial cancer (EC..
dMMR, Dostarlimab-gxly, GlaxoSmithKline, Jemperli
Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer
Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed during or after a prior ..
dMMR advanced solid tumors, Dostarlimab-gxly, GARNET Trial, GlaxoSmithKline LLC, Jemperli, NCT02715284, VENTANA MMR RxDx
Dostarlimab-gxly receives accelerated approval from the FDA for dMMR advanced solid tumours
August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given accelerated approval by the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumours, as dete..